Want to see NMTC full AI Analyst Report?
NMTC Stock Chart & Stats
$4.84
-$0.09(-8.05%)
At close: 4:00 PM EST
$4.84
-$0.09(-8.05%)
Day’s Range― - ―
52-Week Range$2.89 - $6.96
Previous CloseN/A
Volume212.44K
Average Volume (3M)532.45K
Market Cap
$26.11M
Enterprise Value$26.17M
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$206.97K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 19, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding8,702,982
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.69
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$9.67Price Target Upside99.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$10.85M
Bulls Say, Bears Say
Bulls Say
Commercial TractionSharp product revenue growth and recent six-month gains show accelerating procedure adoption and repeat consumable demand. Durable procedure-driven sales momentum supports recurring revenue potential as the company scales clinical adoption and converts trials into routine hospital use.
Gross Margin & Expense DisciplineSustained ~54–55% product gross margins with disciplined SG&A and R&D spending imply favorable unit economics. This margin profile gives room to invest in commercialization while limiting incremental cash burn, improving prospects for eventual operating leverage as revenue scales.
Balance Sheet FlexibilityNo debt plus an expanded at-the-market facility provides durable optionality to raise equity financing as needed without contractual leverage. This flexibility supports continued operations and international rollout funding, albeit at the cost of potential dilution, and reduces short-term solvency risk.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows the business is not self-funding; ongoing losses will require external capital to sustain operations and commercial expansion. This structural cash deficit threatens long-term runway absent meaningful margin expansion or material revenue acceleration.
Near-term Liquidity PressureRapid cash depletion and reduced working capital constrain the firm's ability to fund commercialization, regulatory validation, and inventory for international rollouts. Reliance on receivables conversion and new financing creates execution risk and increases probability of dilutive capital raises in the medium term.
Control & Reporting WeaknessA revenue-recognition restatement signals weaknesses in internal controls and financial reporting. That reduces transparency for partners and investors, may complicate compliance and fundraising, and raises execution risk when coordinating with distributors and regulatory bodies for international expansion.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $2.89 and its highest was $6.96 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $26.11M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is Aug 19, 2026 which is in 45 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on May 12, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.227 by -$0.023.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.58.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 8,702,982 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.227. Following the earnings report the stock price went up 1.386%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
NMTC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and clinical progress — notably 72% Q2 product revenue growth, publication and clinical wins, ISO audit progress, regained NASDAQ compliance, and no debt — alongside strategic hires and partnership momentum. However, material financial and timing challenges temper the optimism: cash balances declined sharply (~57.6%), there was no license revenue this year (vs. $3.0M prior), six-month net loss widened to $3.5M, and gross margins compressed. Several growth catalysts (international rollout, drug delivery commercial availability, spinal cord stimulation timeline) remain contingent on future milestones or partner actions and thus introduce execution and timing risk. Balancing the clear operational wins against the pronounced near-term liquidity and revenue-recognition headwinds yields a neutral overall view.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$9.67
▲(99.72% Upside)